A citation-based method for searching scientific literature

W Timothy Garvey, Donna H Ryan, Nancy J V Bohannon, Robert F Kushner, Miriam Rueger, Roman V Dvorak, Barbara Troupin. Diabetes Care 2014
Times Cited: 54







List of co-cited articles
1183 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Effects of naltrexone sustained-release/bupropion sustained-release combination therapy on body weight and glycemic parameters in overweight and obese patients with type 2 diabetes.
Priscilla Hollander, Alok K Gupta, Raymond Plodkowski, Frank Greenway, Harold Bays, Colleen Burns, Preston Klassen, Ken Fujioka. Diabetes Care 2013
179
68


Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study.
W Timothy Garvey, Donna H Ryan, Michelle Look, Kishore M Gadde, David B Allison, Craig A Peterson, Michael Schwiers, Wesley W Day, Charles H Bowden. Am J Clin Nutr 2012
298
59

Randomized placebo-controlled clinical trial of lorcaserin for weight loss in type 2 diabetes mellitus: the BLOOM-DM study.
Patrick M O'Neil, Steven R Smith, Neil J Weissman, Meredith C Fidler, Matilde Sanchez, Jinkun Zhang, Brian Raether, Christen M Anderson, William R Shanahan. Obesity (Silver Spring) 2012
318
55

Prevention of type 2 diabetes in subjects with prediabetes and metabolic syndrome treated with phentermine and topiramate extended release.
W Timothy Garvey, Donna H Ryan, Robert Henry, Nancy J V Bohannon, Hermann Toplak, Michael Schwiers, Barbara Troupin, Wesley W Day. Diabetes Care 2014
103
51

Controlled-release phentermine/topiramate in severely obese adults: a randomized controlled trial (EQUIP).
David B Allison, Kishore M Gadde, William Timothy Garvey, Craig A Peterson, Michael L Schwiers, Thomas Najarian, Peter Y Tam, Barbara Troupin, Wesley W Day. Obesity (Silver Spring) 2012
284
50

Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Frank L Greenway, Ken Fujioka, Raymond A Plodkowski, Sunder Mudaliar, Maria Guttadauria, Janelle Erickson, Dennis D Kim, Eduardo Dunayevich. Lancet 2010
394
48


A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II).
Caroline M Apovian, Louis Aronne, Domenica Rubino, Christopher Still, Holly Wyatt, Colleen Burns, Dennis Kim, Eduardo Dunayevich. Obesity (Silver Spring) 2013
230
44

A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management.
Xavier Pi-Sunyer, Arne Astrup, Ken Fujioka, Frank Greenway, Alfredo Halpern, Michel Krempf, David C W Lau, Carel W le Roux, Rafael Violante Ortiz, Christine Bjørn Jensen,[...]. N Engl J Med 2015
616
44

Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes: The SCALE Diabetes Randomized Clinical Trial.
Melanie J Davies, Richard Bergenstal, Bruce Bode, Robert F Kushner, Andrew Lewin, Trine Vang Skjøth, Arne Haahr Andreasen, Christine Bjørn Jensen, Ralph A DeFronzo. JAMA 2015
310
40

Multicenter, placebo-controlled trial of lorcaserin for weight management.
Steven R Smith, Neil J Weissman, Christen M Anderson, Matilde Sanchez, Emil Chuang, Scott Stubbe, Harold Bays, William R Shanahan. N Engl J Med 2010
539
38

Weight loss with naltrexone SR/bupropion SR combination therapy as an adjunct to behavior modification: the COR-BMOD trial.
Thomas A Wadden, John P Foreyt, Gary D Foster, James O Hill, Samuel Klein, Patrick M O'Neil, Michael G Perri, F Xavier Pi-Sunyer, Cheryl L Rock, Janelle S Erickson,[...]. Obesity (Silver Spring) 2011
240
38

Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
William C Knowler, Elizabeth Barrett-Connor, Sarah E Fowler, Richard F Hamman, John M Lachin, Elizabeth A Walker, David M Nathan. N Engl J Med 2002
37

Evaluation of phentermine and topiramate versus phentermine/topiramate extended-release in obese adults.
Louis J Aronne, Thomas A Wadden, Craig Peterson, David Winslow, Sarah Odeh, Kishore M Gadde. Obesity (Silver Spring) 2013
89
33

Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.
Steven P Marso, Gilbert H Daniels, Kirstine Brown-Frandsen, Peter Kristensen, Johannes F E Mann, Michael A Nauck, Steven E Nissen, Stuart Pocock, Neil R Poulter, Lasse S Ravn,[...]. N Engl J Med 2016
33


A one-year randomized trial of lorcaserin for weight loss in obese and overweight adults: the BLOSSOM trial.
Meredith C Fidler, Matilde Sanchez, Brian Raether, Neil J Weissman, Steven R Smith, William R Shanahan, Christen M Anderson. J Clin Endocrinol Metab 2011
325
27

Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide.
A Astrup, R Carraro, N Finer, A Harper, M Kunesova, M E J Lean, L Niskanen, M F Rasmussen, A Rissanen, S Rössner,[...]. Int J Obes (Lond) 2012
324
27

Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes.
Rena R Wing, Paula Bolin, Frederick L Brancati, George A Bray, Jeanne M Clark, Mace Coday, Richard S Crow, Jeffrey M Curtis, Caitlin M Egan, Mark A Espeland,[...]. N Engl J Med 2013
27

Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study.
Arne Astrup, Stephan Rössner, Luc Van Gaal, Aila Rissanen, Leo Niskanen, Mazin Al Hakim, Jesper Madsen, Mads F Rasmussen, Michael E J Lean. Lancet 2009
565
25

10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
William C Knowler, Sarah E Fowler, Richard F Hamman, Costas A Christophi, Heather J Hoffman, Anne T Brenneman, Janet O Brown-Friday, Ronald Goldberg, Elizabeth Venditti, David M Nathan. Lancet 2009
24

3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial.
Carel W le Roux, Arne Astrup, Ken Fujioka, Frank Greenway, David C W Lau, Luc Van Gaal, Rafael Violante Ortiz, John P H Wilding, Trine V Skjøth, Linda Shapiro Manning,[...]. Lancet 2017
212
24

Rational design of a combination medication for the treatment of obesity.
Frank L Greenway, M J Whitehouse, Maria Guttadauria, James W Anderson, Richard L Atkinson, Ken Fujioka, Kishore M Gadde, Alok K Gupta, Patrick O'Neil, Donald Schumacher,[...]. Obesity (Silver Spring) 2009
178
22

Benefits of modest weight loss in improving cardiovascular risk factors in overweight and obese individuals with type 2 diabetes.
Rena R Wing, Wei Lang, Thomas A Wadden, Monika Safford, William C Knowler, Alain G Bertoni, James O Hill, Frederick L Brancati, Anne Peters, Lynne Wagenknecht. Diabetes Care 2011
775
22

Reduction in weight and cardiovascular disease risk factors in individuals with type 2 diabetes: one-year results of the look AHEAD trial.
Xavier Pi-Sunyer, George Blackburn, Frederick L Brancati, George A Bray, Renee Bright, Jeanne M Clark, Jeffrey M Curtis, Mark A Espeland, John P Foreyt, Kathryn Graves,[...]. Diabetes Care 2007
872
22

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
Bernard Zinman, Christoph Wanner, John M Lachin, David Fitchett, Erich Bluhmki, Stefan Hantel, Michaela Mattheus, Theresa Devins, Odd Erik Johansen, Hans J Woerle,[...]. N Engl J Med 2015
22

Effect of Naltrexone-Bupropion on Major Adverse Cardiovascular Events in Overweight and Obese Patients With Cardiovascular Risk Factors: A Randomized Clinical Trial.
Steven E Nissen, Kathy E Wolski, Lisa Prcela, Thomas Wadden, John B Buse, George Bakris, Alfonso Perez, Steven R Smith. JAMA 2016
80
22


American association of clinical endocrinologists and american college of endocrinology position statement on the 2014 advanced framework for a new diagnosis of obesity as a chronic disease.
W Timothy Garvey, Alan J Garber, Jeffrey I Mechanick, George A Bray, Samuel Dagogo-Jack, Daniel Einhorn, George Grunberger, Yehuda Handelsman, Charles H Hennekens, Daniel L Hurley,[...]. Endocr Pract 2014
85
20

Pharmacological management of obesity: an endocrine Society clinical practice guideline.
Caroline M Apovian, Louis J Aronne, Daniel H Bessesen, Marie E McDonnell, M Hassan Murad, Uberto Pagotto, Donna H Ryan, Christopher D Still. J Clin Endocrinol Metab 2015
434
20

Obesity and the risk of myocardial infarction in 27,000 participants from 52 countries: a case-control study.
Salim Yusuf, Steven Hawken, Stephanie Ounpuu, Leonelo Bautista, Maria Grazia Franzosi, Patrick Commerford, Chim C Lang, Zvonko Rumboldt, Churchill L Onen, Liu Lisheng,[...]. Lancet 2005
18

Role of orlistat in the treatment of obese patients with type 2 diabetes. A 1-year randomized double-blind study.
P A Hollander, S C Elbein, I B Hirsch, D Kelley, J McGill, T Taylor, S R Weiss, S E Crockett, R A Kaplan, J Comstock,[...]. Diabetes Care 1998
358
18

Association of bariatric surgery with long-term remission of type 2 diabetes and with microvascular and macrovascular complications.
Lars Sjöström, Markku Peltonen, Peter Jacobson, Sofie Ahlin, Johanna Andersson-Assarsson, Åsa Anveden, Claude Bouchard, Björn Carlsson, Kristjan Karason, Hans Lönroth,[...]. JAMA 2014
494
18

Comparison of continuous and intermittent anorectic therapy in obesity.
J F Munro, A C MacCuish, E M Wilson, L J Duncan. Br Med J 1968
105
16

Long-term persistence of hormonal adaptations to weight loss.
Priya Sumithran, Luke A Prendergast, Elizabeth Delbridge, Katrina Purcell, Arthur Shulkes, Adamandia Kriketos, Joseph Proietto. N Engl J Med 2011
615
16

2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society.
Michael D Jensen, Donna H Ryan, Caroline M Apovian, Jamy D Ard, Anthony G Comuzzie, Karen A Donato, Frank B Hu, Van S Hubbard, John M Jakicic, Robert F Kushner,[...]. J Am Coll Cardiol 2014
16

AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY COMPREHENSIVE CLINICAL PRACTICE GUIDELINES FOR MEDICAL CARE OF PATIENTS WITH OBESITY.
W Timothy Garvey, Jeffrey I Mechanick, Elise M Brett, Alan J Garber, Daniel L Hurley, Ania M Jastreboff, Karl Nadolsky, Rachel Pessah-Pollack, Raymond Plodkowski. Endocr Pract 2016
341
16

Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
Steven P Marso, Stephen C Bain, Agostino Consoli, Freddy G Eliaschewitz, Esteban Jódar, Lawrence A Leiter, Ildiko Lingvay, Julio Rosenstock, Jochen Seufert, Mark L Warren,[...]. N Engl J Med 2016
16

Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects.
W Philip T James, Ian D Caterson, Walmir Coutinho, Nick Finer, Luc F Van Gaal, Aldo P Maggioni, Christian Torp-Pedersen, Arya M Sharma, Gillian M Shepherd, Richard A Rode,[...]. N Engl J Med 2010
479
14


Use of twice-daily exenatide in Basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial.
John B Buse, Richard M Bergenstal, Leonard C Glass, Cory R Heilmann, Michelle S Lewis, Anita Y M Kwan, Byron J Hoogwerf, Julio Rosenstock. Ann Intern Med 2011
366
14


Diagnosis and management of prediabetes in the continuum of hyperglycemia: when do the risks of diabetes begin? A consensus statement from the American College of Endocrinology and the American Association of Clinical Endocrinologists.
Alan J Garber, Yehuda Handelsman, Daniel Einhorn, Donald A Bergman, Zachary T Bloomgarden, Vivian Fonseca, W Timothy Garvey, James R Gavin, George Grunberger, Edward S Horton,[...]. Endocr Pract 2008
124
14

Clinical efficacy of orlistat therapy in overweight and obese patients with insulin-treated type 2 diabetes: A 1-year randomized controlled trial.
David E Kelley, George A Bray, F Xavier Pi-Sunyer, Samuel Klein, James Hill, John Miles, Priscilla Hollander. Diabetes Care 2002
167
14

Clinical importance of obesity versus the metabolic syndrome in cardiovascular risk in women: a report from the Women's Ischemia Syndrome Evaluation (WISE) study.
Kevin E Kip, Oscar C Marroquin, David E Kelley, B Delia Johnson, Sheryl F Kelsey, Leslee J Shaw, William J Rogers, Steven E Reis. Circulation 2004
243
14

Effects of intensive glucose lowering in type 2 diabetes.
Hertzel C Gerstein, Michael E Miller, Robert P Byington, David C Goff, J Thomas Bigger, John B Buse, William C Cushman, Saul Genuth, Faramarz Ismail-Beigi, Richard H Grimm,[...]. N Engl J Med 2008
14


Effects of aerobic and resistance training on hemoglobin A1c levels in patients with type 2 diabetes: a randomized controlled trial.
Timothy S Church, Steven N Blair, Shannon Cocreham, Neil Johannsen, William Johnson, Kimberly Kramer, Catherine R Mikus, Valerie Myers, Melissa Nauta, Ruben Q Rodarte,[...]. JAMA 2010
412
14

Effects of cardiac autonomic dysfunction on mortality risk in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial.
Rodica Pop-Busui, Gregory W Evans, Hertzel C Gerstein, Vivian Fonseca, Jerome L Fleg, Byron J Hoogwerf, Saul Genuth, Richard H Grimm, Marshall A Corson, Ronald Prineas. Diabetes Care 2010
245
14


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.